Search research articles
Contact Us
Filters
Showing results (21-30 of 167) with videos related to
Page
of 17
Sort By:
BMC Infectious Diseases
|
January 7, 2022
Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
Jason M Pogue, Yun Zhou, Hemanth Kanakamedala, et al.
Expert Review of Anti-Infective Therapy
|
September 14, 2017
Intravenous fosfomycin for the treatment of hospitalized patients with serious infections
Andrew F Shorr, Jason M Pogue, John F Mohr
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2018
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M Pogue, Robert A Bonomo, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 11, 2015
Optimal Usage of Colistin: Are We Any Closer?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Antimicrobial Agents and Chemotherapy
|
May 19, 2010
Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1
Jason M Pogue, Brian A Potoski, Keith S Kaye
Virulence
|
July 8, 2016
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
Joshua T Thaden, Jason M Pogue, Keith S Kaye
International Journal of Antimicrobial Agents
|
November 24, 2016
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 30, 2016
Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Infectious Diseases and Therapy
|
July 12, 2020
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis, Erin K McCreary, Jason M Pogue
Antimicrobial Agents and Chemotherapy
|
August 22, 2025
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam
Jason M Pogue, Jeffrey Harrington, Walaiporn Wangchinda, et al.
Page
of 17
Search research articles
Search
Showing results (21-30 of 167) with videos related to
Sort By:
Page
of 17
BMC Infectious Diseases
|
January 7, 2022
Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
Jason M Pogue, Yun Zhou, Hemanth Kanakamedala, et al.
Expert Review of Anti-Infective Therapy
|
September 14, 2017
Intravenous fosfomycin for the treatment of hospitalized patients with serious infections
Andrew F Shorr, Jason M Pogue, John F Mohr
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2018
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M Pogue, Robert A Bonomo, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 11, 2015
Optimal Usage of Colistin: Are We Any Closer?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Antimicrobial Agents and Chemotherapy
|
May 19, 2010
Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1
Jason M Pogue, Brian A Potoski, Keith S Kaye
Virulence
|
July 8, 2016
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
Joshua T Thaden, Jason M Pogue, Keith S Kaye
International Journal of Antimicrobial Agents
|
November 24, 2016
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 30, 2016
Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?
Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Infectious Diseases and Therapy
|
July 12, 2020
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis, Erin K McCreary, Jason M Pogue
Antimicrobial Agents and Chemotherapy
|
August 22, 2025
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam
Jason M Pogue, Jeffrey Harrington, Walaiporn Wangchinda, et al.
Page
of 17